Search | Clinical Trials Finder

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Osteoarthritis, Knee
Interventions: Celution Device, Placebo; Device · Other
Lead sponsor: Cytori Therapeutics; Industry
Eligibility: 40 Years to 69 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 11
States / cities: Mesa, Arizona • Little Rock, Arkansas • La Mesa, California + 8 more

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more

Conditions: Hereditary Periodic Fevers
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio

Conditions: NMO Spectrum Disorder, Spasticity, Muscle
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Michael, Levy M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions: ABBV-RGX-314, Ranibizumab (LUCENTIS®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 89
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more

Conditions: Labor Pain, Pregnancy
Interventions: combined spinal epidural analgesia, late analgesia (systemic); Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,026 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Elevated Intraocular Pressure
Interventions: Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%; Drug
Lead sponsor: TearClear Corp; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Garden Grove, California • Glendale, California • Mission Hills, California + 16 more

Conditions: Brain Concussion
Interventions: Branched Chain Amino Acids, Placebo solution; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 11 Years to 34 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: BMS-986166, Placebo matching BMS-986166; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Postoperative Pain
Interventions: Bupivacaine, Saline Solution; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Fresno, California

Conditions: Early Child Development
Interventions: Group sessions, Group+Home sessions, Booster sessions, Fathers invited; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 15 Years and older
Enrollment: 1,152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Liraglutide, Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 45
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more

Conditions: Von Willebrand Disease
Interventions: Vonicog alfa, Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 16
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more

Conditions: Intraoperative Floppy Iris Syndrome
Interventions: Brimonidine Tartrate; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 100 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Non-healing Wound
Interventions: CeFAZolin Injectable Solution; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain
Interventions: bupivacaine liposome injectable suspension, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Mobile, Alabama • Englewood, Colorado • Miami, Florida + 9 more

Conditions: Clostridium Difficile Infection
Interventions: Clostridium difficile vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 17,535 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 220
States / cities: Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more

Conditions: Pain
Interventions: Infiltration of local anesthetic, Normal Saline Injection; Procedure
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Obesity
Interventions: intravenous acetaminophen, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Child Abuse, Intimate Partner Violence, Secondary Prevention, Parenting
Interventions: Pregnant Moms' Empowerment Program, Reminiscing and Emotion Training, Pregnancy - Active Control, Enhanced Case Management; Behavioral
Lead sponsor: University of Notre Dame; Other
Eligibility: 3 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Notre Dame, Indiana • Madison, Wisconsin

Conditions: Morbid Obesity
Interventions: propofol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Viral Infection
Interventions: UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo; Drug
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Children, Lacerations, Procedures, Child, Pain
Interventions: hydrocodone/acetaminophen, Sugar water; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 2 Years to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Neuraxial Versus Systemic Analgesia for Latent Phase Labor Effect on Rate of Operative Delivery

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

BCAA Supplementation for Concussion

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Peripheral Nerve Blocks for Major Lower Extremity Amputations

Testing Means to Scale Early Childhood Development Interventions in Rural Kenya

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Pupil Dilation for Treatment of IFIS

Antibiotic Tumescent For Chronic Wounds

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

Clostridium Difficile Vaccine Efficacy Trial

Local Infiltration Analgesia for Hip Arthroscopy

Prospective, Double Blind, Placebo Control, Bariatric IV Ace

The Unique and Combined Effects of Prenatal and Early Childhood Programming on Child Maltreatment: Examining Mechanisms of Change

A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair